<DOC>
	<DOCNO>NCT00642499</DOCNO>
	<brief_summary>The primary purpose study determine dronabinol effective prevent treat nausea cause HAART ( highly active anti-retroviral therapy ) HIV AIDS patient</brief_summary>
	<brief_title>Dronabinol Versus Placebo Treatment Prevention Highly Active Anti-Retroviral Therapy ( HAART ) -Related Nausea Vomiting</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>Adherence prior current HAART compromise , HAART discontinued/interrupted due nausea/vomiting ; begin HAART switch regimen time screen study produce significant nausea and/or vomit regimen zidovudine protease inhibitor ( without low dose ritonavir ) . Subjects recent ( within 30 day randomization ) current opportunistic infection neoplasm characteristic AIDS ( Category C CDC Classification System HIV1 infection , 1993 Revised Version ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>nausea</keyword>
	<keyword>vomit</keyword>
	<keyword>HAART</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>HIV Infections</keyword>
</DOC>